Paris, France – October 2, 2009 – ExonHit Therapeutics (Alternext: ALEHT), a fast emerging healthcare player developing innovative molecular diagnostic tests and therapeutics for neurodegenerative and cancer indications, is pleased to announce that Loïc Maurel, M.D., President of the Management Board, will be attending and presenting at the BioContact Québec partnership symposium to be held at the Château Frontenac, Québec on October 7 & 8.
ExonHit Therapeutics’ presentation will take place on Thursday, October 8, at 9:30 am in Salle Bellevue.
About ExonHit Therapeutics
ExonHit Therapeutics (Alternext: ALEHT) is a fast emerging healthcare player active in both therapeutics and diagnostics. The Company is applying its proprietary technology, based on the analysis of alternative RNA splicing, to develop innovative molecular diagnostic tests and therapeutics for neurodegenerative and cancer indications. ExonHit has a balanced investment strategy with internal development programs and strategic collaborations, in particular with bioMérieux and Allergan.
ExonHit is headquartered in Paris, France and has U.S. offices in Gaithersburg, Maryland. The Company is listed on Alternext of NYSE Euronext Paris. For more information, please visit http://www.exonhit.com.
